Published DateClear

Start Date

End Date

Category

• Pipeline3
• Business1

Organizations

• Bausch + Lomb81
• Eyes On Eyecare62
• Alcon, Inc.53
• American Optometric Association44
• Harrow35
• Glaukos31
• Topcon Healthcare26
• Regeneron25
• Coopervision23
• Aldeyra Therapeutics21

Tags

• Dry Eye Disease3
• Clinical Trials2
• Eye Drops2
• CEO1
• Dry Eye1
• Eye Drop Solution1
• Glaucoma1
• Leadership1
• Licensing Agreement1

• Organizations: Stuart Therapeutics ✕

Clear all

Business

Leadership watch: Samsara, Claris Bio, Staar Surgical, Wills Eye, and more

Leadership changes are underway in the eyecare space—and we’ve got the latest.

Pipeline

Stuart Therapeutics reports initial phase 3 DED eye drop data

Results on ST-100 (vezocolmitide), a collagen mimetic peptide, support its role as a fast-acting resolution for dry eye signs and symptoms.

Pipeline

Stuart Therapeutics initiates phase 3 DED trial for vezocolmitide

Topical formulation aims to improve tear production, symptom relief, and reduce ocular surface damage.

Pipeline

Glaukos acquires global rights to Stuart Therapeutics' neuroprotection glaucoma asset

Proprietary therapeutic has been shown to function independently of IOP control.